CAR T therapy targeting BAFF-R for certain NHL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1 study tests a new type of immune-cell therapy (CAR T cells) that targets BAFF-R to treat certain relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). It aims to see if the treatment is safe and can shrink lymphoma in people who have tried prior therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older, and you can do daily activities at a limited level (ECOG 0–2).
- Your lymphoma is confirmed as B-NHL, such as diffuse large B-cell lymphoma, mantle cell lymphoma, or follicular or marginal zone lymphoma, and your tumor shows BAFF-R.
- You have measurable disease, either on a CT/PET scan or disease found in places like blood, bone marrow, GI tract, skin, or spleen.
- Your body tests show you can safely receive treatment: enough white cells, platelets, kidney function, liver function, and heart/lung function.
- You must not have certain infections; for example, no active HIV, hepatitis B, or hepatitis C (or viral load must be undetectable if you have it).
- You must not be pregnant or breastfeeding, and you must use reliable contraception for 3 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells that are modified to find and kill cancer cells in the blood or lymph nodes. It's for people whose leukemia or lymphoma has come back or did not go away after previous treatments.
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
This Phase 1 study tests a new immune cell treatment (BAFF CAR-T) for people with non-Hodgkin lymphoma that has come back or did not respond well to treatment. It aims to see how safe it is and whether it can help control the lymphoma.
This trial tests a new CAR-T cell treatment that targets a protein called BAFFR on cancer cells. It is for people with B-cell lymphoma that has come back or not responded to previous treatments.
This trial tests a new type of immunotherapy called BAFF-R CAR-T cells for people with B-cell lymphoma that has come back or not responded to treatment, and whose cancer cells do not have the CD19 protein. The treatment uses your own immune cells, modified to target and kill the lymphoma cells.
This trial tests a new kind of immunotherapy called CAR T-cells that are designed to find and attack a protein called BAFF-R on your lymphoma cells. It is for people with certain types of B-cell lymphoma that have not responded well to at least two earlier treatments.
Hear when a new Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.